Table 2.
Change in hemoglobin from baseline to Week 13
| QW | EDS | Difference | |
|---|---|---|---|
| (n = 374) | (n = 378) | (QW - EDS) | |
| LVCF method | |||
| na | 374 | 375 | |
| Least squares mean (95% CI) | 0.90 (0.74, 1.07) | 0.95 (0.79, 1.11) | -0.04 (-0.26, 0.17)b |
| Available data method | |||
| na,c | 257 | 253 | |
| Least squares mean (95% CI) | 1.29 (1.10, 1.47) | 1.16 (0.98, 1.34) | 0.13 (-0.11, 0.36) b |
aThree patients in the EDS group were missing screening hemoglobin and were omitted from the ANOVA model
bThe least squares means and CIs of the treatment difference were computed from an ANOVA model after adjusting for the stratification factors at randomization (chemotherapy cycle length, screening hemoglobin, and tumor type)
cPatients missing hemoglobin values at Week 13 were omitted from the analysis
QW = once weekly; EDS = extended dosing schedule; LVCF = last value carried forward; CI = confidence interval; ANOVA = analysis of variance